Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study. (2022)
Attributed to:
Personalised management of atypical haemolytic uraemic syndrome
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1136/bmjopen-2021-054536
PubMed Identifier: 36123058
Publication URI: http://europepmc.org/abstract/MED/36123058
Type: Journal Article/Review
Volume: 12
Parent Publication: BMJ open
Issue: 9
ISSN: 2044-6055